Serum Biomarkers in Parkinson's Disease at Different Stages

Not Applicable

Recruiting

• Conditions: Parkinson Disease
• Interventions: Procedure: blood sample

• Registration Number: NCT05769699
• Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Brief Summary

* Determine clinical characteristics of parkinsonian patients in various stages of disease;

* Measure peripheral neurodegeneration, synaptic, and inflammation biomarkers in a population of parkinsonian patients at various stages of disease.

* Measure vesicular neurodegeneration, synaptic and inflammation biomarkers

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-10
• Status Verified: 2023-02
• Study First Submitted: 2023-02-28
• Study First Submitted QC: 2023-03-13
• Last Update Submitted: 2023-03-13
• Study First Posted: 2023-03-15
• Last Update Posted: 2023-03-15
• Primary Completion: 2023-12-30
• Study Completion: 2027-11-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients diagnosed with idiopathic PD according to Movement Disorders Society (MDS) criteria;
• Age: 18-80 years;
• Signature of informed consent to participate in this study

Exclusion criteria.

• Women pregnant
• Inflammatory or autoimmune diseases

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Biomarkers	blood sample	-

Primary Outcome Measures

Name	Time	Method
Determine clinical characteristics of parkinsonian patients in various stages of disease	3 years	Determine clinical characteristics of parkinsonian patients in various stages of disease by means of NMS score changes.
Determine biooogical characteristics of parkinsonian patients in various stages of disease	3 years	dosage of serum IL-1b, IL6, IL-5, IL-4, IL17, TNFa, IFNg, IL10, total-alpha-synuclein, NfL, BDNF (ng/ml for all)

Trial Locations

Locations (1)

Flavia Torlizzi; 🇮🇹 Roma, Italy